Acute, subacute, chronic toxicity and mutagenicity studies of rifaximin (L/105) in rats.
Acute, subacute and chronic toxicity-mutagenicity studies of rifaximin (L/105), a new semisynthetic rifamycin SV antibiotic, were conducted in rats. The oral LD50 value for this species was greater than 2000 mg/kg. Rifaximin given orally to rats up to 6 months produced no evident adverse effects up to 100 mg/kg. The moderate effects noted were probably due to the topical action of the drug. Rifaximin did not show any mutagenic activity when compared with mutagenic standards.
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D005260:Female; D008297:Male; D009152:Mutagenicity Tests; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D012294:Rifamycins / Q000633:toxicity*; D000078262:Rifaximin
D012294:Rifamycins; D000078262:Rifaximin